Ra Pharmaceuticals has started dosing patients in a Phase lb clinical trial assessing RA101495 SC in patients with renal impairment.

The multi-centre, open-label trial is designed to evaluate and compare the pharmacokinetics (PK) profile of RA101495 SC in patients with renal impairment with subjects with normal renal function.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The trial expects to enrol around 16 subjects, including eight patients with severe renal impairment and another eight healthy control subjects with normal renal function.

During the trial, each patient will be given a single, SC dose of 0.3mg/kg of RA101495.

The trial eventually aims to assess RA101495 SC in complement-mediated renal diseases, including atypical hemolytic uremic disorder (aHUS) and lupus nephritis (LN).

“The initiation of dosing in this Phase lb trial is a meaningful step for advancing RA101495 in multiple complement-mediated renal indications.”

Ra Pharmaceuticals president and CEO Doug Treco said: “The initiation of dosing in this Phase lb trial is a meaningful step for advancing RA101495 in multiple complement-mediated renal indications.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“The convenient, once-daily, SC, self-administration dosing profile of RA101495 provides a compelling alternative to currently available, intravenously-administered (IV) therapies, and we continue to work toward providing a differentiated treatment option for these patients and addressing this significant unmet need.”

Ra Pharmaceuticals is currently developing RA101495 as a new, subcutaneously-administered (SC) inhibitor of complement component 5 (C5).

The company is also investigating RA101495 SC under a Phase ll clinical trial for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and generalised myasthenia gravis (gMG).